This year, we have grown from 13 small partners to 30 small partners.

In this year, we obtained 6 core invention patents. We devoted ourselves to research and development. The small nano antibody bears the hope of curing disease. These achievements will become a solid foundation for our continuous progress in the field of antibody medicine.

‍

This year, we carried out the second-level biosafety experiment filing project, which means that the laboratory is gradually on the right track. Luoqi Biology has a sound biosafety laboratory management system and organization, and a sound biosafety laboratory management system.

In this year, we are also improving our academic influence and publishing many academic papers with high scores.

This year, we signed a contract with Kaihui Ruizhi Biological on the LQ001 nanoantibody project to jointly promote the pharmaceutical research and development of the new tumor immunotherapy nanoantibody project LQ001 to meet the requirements of clinical application.

Boys and girls, thank you for having you all the way. Let's go hand in hand, grow in Loqi, develop in Loqi, and take off in Loqi!

Shanghai Luoqi Biomedical Technology Co., Ltd

Shanghai Luoqi Bio-pharmaceutical Technology Co., Ltd. was founded in October 2017, located in the Shanghai International Medical Park. The founder, Dr. Wan Yakun, is committed to the research and development of new tumor immune drugs based on camel antibodies and the transformation of results. At present, the company has established a product chain including multiple new drug varieties of nano antibody/bispecific antibody, covering the fields of tumor, fundus disease, autoimmune disease, cardiovascular disease and other diseases.